Materialise's strong earnings beat streak and technical breakout are offset by margin compression and value-trap signals, with the stock already at its prior price target.
Thesis pillars
- Margin Compression Value Trap→Stable
- Earnings Beat Streak→Stable
- Technical Breakout Momentum→Stable
- +1 more pillar — see the Why tab for full reasoning
Materialise NV (MTLS) Stock Analysis
Catalyst-Driven edge
Technology · Software - Application
Hold if already holding. Not a fresh buy at $8.56, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.9% away).
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The... Read more
Hold if already holding. Not a fresh buy at $8.56, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 21d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent developments
updated 2026-10-07Recent Developments — Materialise NV
Latest news
- NEWS Materialise To Resume Stock Buyback Plan, Effective Aug. 31 — benzinga Aug 28, 2026 positive
- NEWS Full Transcript: Materialise Q2 2026 Earnings Call — benzinga Aug 27, 2026 neutral
- NEWS Materialise Affirms FY2026 Sales Guidance of $317.813M-$329.455M — benzinga Aug 27, 2026 positive
- NEWS Materialise Q2 EPS $0.07 Beats $0.04 Estimate, Sales $79.841M Beat $68.500M Estimate — benzinga Aug 27, 2026 positive
Generated 2026-08-31T11:27:05Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $8.56, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (2.9% away). Chart setup: No clear chart pattern; technical signals are mixed. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $9.84 (+15.0%), stop $8.02 (−6.7%), A.R:R -0.9:1. Score 5.3/10, moderate confidence.
Take-profit target: $9.84 (-12.6% upside). Target $9.84 (+15.0%), stop $8.02 (−6.7%), A.R:R -0.9:1. Stop-loss: $8.02.
Analyst target reached - limited upside remaining; Near 52-week high (2.9% away); V7 low-quality RISK_OFF penalty: -0.5 (Q=5.0).
Materialise NV trades at a P/E of 30.6 (forward 33.2). TrendMatrix value score: 5.4/10. Verdict: Hold.
9 analysts cover MTLS with a consensus score of 4.3/5. Average price target: $9.
What does Materialise NV do?Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas,...
Materialise NV provides additive manufacturing and medical software tools, and 3D printing services in the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three segments: Materialise Software, Materialise Medical, and Materialise Manufacturing. The Materialise Software segment offers proprietary software through programs and platforms that enable and enhance the functionality of 3D printers, and printing operations. Its software interfaces between various types of 3D printers; and various software applications and capturing technologies, including computer-aided design/computer-aided manufacturing packages and 3D scanners; a MES, software providers. This segment serves 3D printing machine manufacturers; production companies and contract manufacturers in automotive, aerospace, consumer goods, and hearing aid industries; and 3D printing service bureaus through its sales force, website, and third-party distributors. The Materialise Medical segment provides medical software that allows medical-image based analysis, planning, and engineering, as well as patient-specific design and printing of surgical devices and implants. It serves medical device companies, hospitals, universities, research institutes, and industrial companies. The Materialise Manufacturing segment provides 3D printing services, design and engineering services, and rapid prototyping and additive manufacturing of production parts to customers serving the automotive, consumer goods industrial goods, semiconductor, art and architecture and aerospace markets. The company has collaboration agreements with Zimmer Biomet Holdings, Inc.; Encore Medical, L.P.; DePuy Synthes Companies of Johnson & Johnson; Limacorporate Spa; Mathys AG; Smith & Nephew Inc.; Corin Ltd; Medtronic Inc.; and Abbott Laboratories Inc. Materialise NV was incorporated in 1990 and is headquartered in Leuven, Belgium.